GE pushes Hexvix technology to the fore in focus on bladder cancer
This article was originally published in Clinica
Executive Summary
In a bid to capitalise on a largely untapped opportunity within the bladder cancer market, GE Healthcare (Chalfont St Giles, UK) is driving forward the global commercialisation of its Hexvix (hexaminolevulinate) fluorescence cystoscopy technology.